OMER OMEROS CORP Contract Awards 8-K Filing 2025 - Statistical Analysis On February 20, 2025, Omeros Corporation announced results from a statistical analysis of their narsoplimab treatment for a specific blood condition related to stem cell transplants.Get access to all SEC 8-K filings of the OMEROS CORP